Infectious Disease Department, The Indus Hospital, Karachi, Pakistan.
The Indus Hospital Research Centre, The Indus Hospital, Karachi, Pakistan.
Int J Infect Dis. 2018 Nov;76:73-81. doi: 10.1016/j.ijid.2018.08.020. Epub 2018 Sep 8.
The primary objective was to determine the association between histopathological and microbiological findings in patients clinically suspected to have tuberculous lymphadenitis. A secondary objective was to assess the diagnostic utility of GeneXpert in lymph node specimens.
This was a single-centre prospective cohort study, performed in the Infectious Disease Clinic at The Indus Hospital. Three hundred and forty-one adult patients with chronically enlarged, accessible lymph nodes were enrolled after obtaining verbal consent, between February 2013 and April 2016. Tissue specimens were processed for histopathology, acid-fast bacillus (AFB) microscopy, AFB culture, and GeneXpert. Based on these results, anti-tuberculosis therapy (ATT) was prescribed. Clinical characteristics and treatment outcomes were recorded.
There were 297 evaluable patients; 74.4% were diagnosed with tuberculous lymphadenitis (TBLA), 6.7% with a malignancy, and 12.8% with reactive nodes. TBLA was diagnosed on suggestive histopathology in 89.6% of cases, followed by GeneXpert (32.6%), mycobacterial culture (26.6%), and AFB smear positivity (12.5%). The sensitivity of GeneXpert was 65.7% when assessed against AFB culture. Drug resistance was displayed by 8.2% of GeneXpert-positive cases and 11.7% of culture-positive cases. The majority of TBLA patients (88.7%) responded favorably to ATT.
In light of laboratory evidence, a quarter of patients suspected of TBLA had an alternative diagnosis, highlighting its importance in avoiding over-treatment and diagnostic delays in malignancy. Although sensitivity is poor, the demonstration of drug resistance by both GeneXpert and AFB culture represents a useful tool to guide treatment.
本研究旨在确定临床上疑似患有结核性淋巴结炎的患者的组织病理学和微生物学发现之间的关联。次要目标是评估 GeneXpert 在淋巴结标本中的诊断效用。
这是一项单中心前瞻性队列研究,在 The Indus 医院的传染病科进行。在 2013 年 2 月至 2016 年 4 月期间,获得口头同意后,共纳入 341 名患有慢性肿大、可触及的淋巴结的成年患者。对组织标本进行组织病理学、抗酸杆菌(AFB)显微镜检查、AFB 培养和 GeneXpert 检测。根据这些结果,开具抗结核治疗(ATT)。记录临床特征和治疗结果。
有 297 例可评估患者;74.4%诊断为结核性淋巴结炎(TBLA),6.7%诊断为恶性肿瘤,12.8%诊断为反应性淋巴结。在 89.6%的病例中,TBLA 通过提示性组织病理学诊断,其次是 GeneXpert(32.6%)、分枝杆菌培养(26.6%)和 AFB 涂片阳性(12.5%)。当与 AFB 培养相比,GeneXpert 的敏感性为 65.7%。8.2%的 GeneXpert 阳性病例和 11.7%的培养阳性病例显示耐药性。大多数 TBLA 患者(88.7%)对 ATT 反应良好。
鉴于实验室证据,四分之一疑似 TBLA 的患者有其他诊断,这突出了其在避免过度治疗和恶性肿瘤诊断延迟方面的重要性。尽管敏感性较差,但 GeneXpert 和 AFB 培养均显示耐药性是指导治疗的有用工具。